Stock of the Day

Today's Trend

Qiagen N.V. (NYSE:QGEN) shares were under pressure as investors weighed a new intellectual-property liability against several product and regulatory developments. The most immediate concern was a patent-infringement verdict involving Parse Biosciences, while modestly mixed earnings revisions limited the positive impact of Qiagen’s product launches and FDA clearance.

• The FDA cleared Qiagen’s QIAstat-Dx BCID GPF Plus AMR Panel, giving the company its first entry into the U.S. bloodstream-infection testing market. The automated test detects 20 bacterial and fungal targets plus 10 genetic antimicrobial-resistance markers and runs on a platform with more than 5,200 placements globally, creating potential for added instrument and consumables revenue. Could Qiagen Stock Win as Its FDA Clearance Opens a New Diagnostics Market?
• Qiagen launched QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic-acid extraction. The product builds on a QIAsymphony installed base of more than 3,300 systems and could support recurring demand for Qiagen’s laboratory consumables and assays. QIAGEN Launches QIAsymphony Connect
• Zacks Research made small, mixed adjustments to its forecasts. It maintained a “Hold” rating and kept fiscal 2026 EPS at $2.43, while raising fiscal 2028 EPS to $2.91 from $2.88. However, fiscal 2027 EPS was lowered to $2.60 from $2.63, suggesting limited near-term earnings momentum. Qiagen analyst estimates
• A Delaware jury found Parse Biosciences, which Qiagen acquired, willfully infringed three patents exclusively licensed to Scale Biosciences, a 10x Genomics subsidiary. Potential damages, royalties, or other remedies could increase costs and create uncertainty around Parse’s business, although the financial impact was not disclosed. 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences